Stemrim Inc. · TSE:4599
Stemrim — Investor Presentation (October 2026)
59 slides from Stemrim's investor presentation, Oct 30, 2026
Slide 1: Business plan and growth potential
S SSE HIRO FA Rett ICH Ss = PRASAAT AU L GEFI-F:4599) 2026108308 ©2 stemrim
Slide 2: PURPOSE: Empower Life Regeneration
PURPOSE MESO OPERR Empower Life Regeneration. |— BRS °CmeAEORREMABK
Slide 3: 1. Company overview
1. EVDRREF IRR
Slide 4: Company overview
AREF IL AMAL “MMRDA IRR BIA HORSES LC, Ran O RFE SUSHE MRTTHESE ST LUAP IRF SCE CMA SBOBRET ID Esa _LHE TC, AIC 1O~ 1 SFR OREN OSAKA UNIVERSITY RRS HL ] IaSSeHE a: ° OTVUF4 pas e pa ae (i ROBB C StemRiM ) [m= 9:2. E OR, axe Cc man) RHR HARRI 1 CY AsO RVGIC—HRCL THSNSEMRA VIWAR—UIRA ESE ia O BAPE ERI
Slide 5: Company overview and listing
RIEERCOESRHICOWT Bi (i865) (2014118) BERS ER MRALICL FEDRBBORBICNS SHR APES DEANS RAIL TUS EOMORN (20206A) ROAR X— SRE BERBER LIVLFK(HMGBIATFE) RISBULA ME ARK CUCBATSERMOERMBA, RUENSORERISRAM ICES SSHRCSI SHIR, SHRICH CHAMEAMB LOATH ROERAAE COMA, BE PARISI SEOO BRE HEN OS TCU ZENSTS. ST ROMMCLTAT AU
Slide 6: Financial summary and July 2026 results
2026 7A RAZ +2026 7A RIS AE ICS YT IVAK-UIRA, RA-BEO SESS <, BRAMALL BIRENIANRVF V-EWUSEDRAEF IE, FRE SME. HAAR A C53. 7AORMARERA. 2027F7AHOFMRMRAMIL 5.3 ~ 20.1187 ARR IC RS RRR: 13~171A, —MBBACKORRRH:2.368A~3. 1A) ORAS CHY. BHR C2Z028FETO RENSHAMAAWMOLODRE EER. (84t: BPR) 20225758 | 202347AM 202347
Slide 7: Founder and CSO profile
EF se A SUCRE ERCSO(Chief Scientific Officer) ) Ik, #5: RBBESW AE KBEO BSE COWBRUE QBIC. BARS MIC KSRRBEOAMAEHICSA. HMGB1S3A OR 4S XHI ALA ARAL, AERA BRL VE ARPIFRILICLFE EMF. AR CAMECRE SHEL, BERSERCWS ME CARRS EEL RR RERCSO E> EH BA BARRASS 1990% 4A ShiiAtoF ESR RARRMA BARR RBASS 1990%10R *HLII7—-
Slide 8: Investment highlights
PFC BA FEA il AThLUATCIE. ARAFESLOBEBSEF HAA PEO OE &, HE REO DT BARA aks DS. RERO BERS ERO BIS, © 5 /CFFRRPRSERIC RAF KORN REV ORUCZSEC, BEBSER OR FUCIC IS ERAT OL ALAA NICHE BS tee A all Uf HABE (6h PH ARHMEORME eRe SHURE LR LOR RRTPY SATIRETC-RLT URAC BIT S BEB RHE “ET )LPOCHEM FUE OSY:
Slide 9: 2. Regeneration-inducing drug platform
2. BERS RR IVLIb
Slide 10: Regeneration-inducing drug concept
fF XAIAL EB TER OMIT ICL MICE AOA OA SAA LAOS SB © kX Bikes MROBEDRE @ BERBER ORS [ WHEa FX @ BMP SHE MICHA 7 7s @] fag ( : _ Qntmuex'ons )| | jae | \ | a ae = Vv / \ ln AS NS ) f “Ul AARON BESAS
Slide 11: Mechanism of regeneration-inducing drugs
+ ASHES tS XDI ALORA BEREXAIALOBIAL, RABSWRRABEBAO BBE CD BRC FETS EMERCREKREORR® TEMBER (BIA) IA THAIS — TID BEAIO SS |ARREL,. RMB ORG CHSRRCAREREL TSM, ARR ZK aie (BB) CA BAS—TIORM (SEY. DS DRUM CB AIRC ARREST So BME HGS SRB EHF DBL MPSS CTFTE ST SED, FER AKIRA O BGO 5 SEBS MIIORAL, RROBLRAILADNS.
Slide 12: Mechanism of regeneration-inducing drugs
FA ARB tS XNIALOBR FRBADS MRE TLE OR ERTE XA = ZL EAR RR MAE RALEICEDDNST, RROBA SHB RR RG MIORA MRENLELEA SMAHIFEX DZ AiO AB onze: POSH Vol.265 No.5 463-468;2018 BRED H:4.1(1);7-12,2019 BRR ARMAS (EHRA)
Slide 13: Mechanism of regeneration-inducing drugs
FA ARB tS XNIALOBR STEARATE LTE C REID 9OAK—IXN=ALEER ERROR RAMPART (FBZ AKFAIE BE O B28) iam | > & > sa RRA @: - MB@AOHMGBI1ICAAST —— BAD ne ca Sotes I aes ERAN SAWINS its SRR AREF aS Pe AS DST MBAO MIAH MIA > 4):1996-200: 2011 Apr 19:108(16):6609-14
Slide 14: HMGB1 peptide and its action
REIMDRHMGBINDFRERO EIS HMGB19YINIDA-BoxE X14 YA{EFaRL TRAD BWAT FR ERE BIR C23 C45 HMGB1 “Y IK HMGB192/\7 [dB ERIE AHCT SEB SCEAAS FCHY, B-boxAICRERDEBS SS BRRBATHER X ADIMFES SCEMASNTWNS. DINIAEXTIO REESE | cS | RREMHRERCSO EHRA (FRESE ORG CSS BSE MATHER X41 > (KOI 2EXTD)ISA-bOXAICTHET SCEMBASAICRI
Slide 15: 3. Regenerative medicine market
3. BERBER ORM
Slide 16: Regenerative medicine landscape
AAESETE ARO lols St HMA ERO SEI CSM IS SAARC MEL, BISA ESE CHEM BERSER DUNC TSO RO MAS Ma CS DAFF ( FEI EOF ERPS) erin 10 20 0 a?) oh e itera (PaAmRaNR= ESHA) CSO: REBT (HESS) a HES EUR RE SE ENISO SATE 2 Re: Bae #CS9:N—-4¥-2AF—II, CSI THBOCRRME CVSCHONTUNS
Slide 17: Cell therapy challenges
SAREE Se SF MIO 216 BEGMER NSS SERIE EAN IS, MUS AEC IMHEAEEAL TUS 22 stemrim SRS ie Sanaa I) Lp (HATHA SE oe) 17 BE aa Ci) (att) (Mb) Aa Rea eh tithe at LE te re ODEN UR oles OEY cle ae REELS CIHGDS CE AU MALE AMAP OMAR LY MEDRRBEN TU SHA OMEN E THSLBASNTS. Boece sie lasencusen
Slide 18: Patient numbers by target disease
BARES ONRRS Aa BERGER DHSS SHARES RS | COBROIRD RAD SREY —F yb GBB cee SHEERS *B:1,3505A"8 hE #KE12.15A3! fot a 1) 9A Aueeoam #69 A? 1.25" Se aman GE rhc—tsax Ztt Semi #KH:3,2505A29 0. — O5BAZ 4 O00BA: 53. | 53.6544 KB:1,6505A%20 FAR HEARS AtEMA) AMER (ENA) igs 2 eae 1388S 50BA"¢ 18.7BA7 WBA ADRES (
Slide 19: Target disease patient numbers (notes)
HERE ER ON RRA (SF SCM) <BEx> “EERO DAZE BAA PRAIA | OBER *18: Brain Trauma Foundation, Summary health statistics for U.S. *2:BANDILUP EES adults: National Health Interview Survey, 2010. National Center for +3 :RESGA ER20F7TANEPMOMECAIC EM SREMRICOWTREB Health Statistics. Vital Health Stat. 2012;10(
Slide 20: Advantages over cell therapy (1)
MMRDA RK OD Lee tt (1) FAAMR AS MRAILS COHAN S ATS 1 EE RET “SSS OP ABD SME LAME CHEE (BM) TS, Rat VRUYIAZ o Ber =) SAE BES Maia OxBE “REISE IBN, RICE SE SAGUAB OMA EMAS. #1 ABD SDBINDED FOI NIA CEAHM OME BAMA (BIS LBROMBIC BASSAS, #2:4E MMT SCANS DINGS SR #3:VMJy92x9070FP—t (Matrix metalloproteases
Slide 21: Advantages over cell therapy (2)
MRDARK O Lee itt (2) MSRM HOMER E17 5 BE CHAE TELUS, BERBER ONE CH OMAERA OWELZ ALBWER CDV SMRARMRORS BAe UBB & ‘N A ARB Rage BRAS ; a ial (heist SAH Mls, FAH CHBENS ET ISR AEP MIO: PRS acts . FBAMABS IT SCC RR iia RE ante, ae aRRETI ERE TI A ABBE sane AA SERED b IMSCsMiamlc dF SMRIS, CRAFT SMIAD! I
Slide 22: Advantages over cell therapy (3)
MLARK O Lee iztt (3) BERGER SES LMS RREAUS. TREE MLAMERR ChHSED, $885 -TEOM CHRROBLERS Amt VEIO—/ VL RICA ESEMME A \SBEERSRAOTO—/ VU RMLO RA m MOBIC eRE ERE Bi CPCS ORGS S EIRTEL. AKERS OYE | eciemne 3 MEBs WELEMSHLI SUE Bh HADES, IAKEMRD> BELT SUR BERSES ICHWTSCNSOMMISRELAU D> THE LOBE > 58 LOB ns
Slide 23: Strengths of regeneration-inducing drugs
BERS ER ORMEECH BESMER id CW OMTARE LAMERROMEO RM ERIMAS RtReE MBER {CER OC sewstemsicenncss A ARUP SAGIAG ICE MG CES O SOAS MEMES MAOLPALEMAT SIEM Ai ROPXNIALAPABLETU BOLE CL aioe FORMA SYbI4—L CBW EAN-CTSSABE IEE ANCE SAREE B59 S0RKAONEREAS O Bt SMERR CH), REABIEN RF QO xrnsicscomesin TUN = eee -
Slide 24: Strengths of regeneration-inducing drugs (2)
BERS ER ORMItEKXH(2) BERMER' (SCRLOMAROBADS ORME MORATIE BAAEYAI*1 SEB FAB A SBLICLOD AAC OPEIRE iPS#H#e = ES#HRa a Fy D> (RY ESP HERD @LOBn tb SHH OMI? ChORRERL TEDIEL HFRS SCL JBRBBE 7ICIR ADDS HERE BASIE se OPSRBIICRRSNS. {HAHAH RAREO RA MWA OMIVE ET SCUCLS RIE URD *1:TiPSHRID EL Het tS HO BU BIR
Slide 25: Strengths of regeneration-inducing drugs (3)
BERS EX OBWttkcX (3) FERTAGMMLM ARMM S7 LF I~ EBT ©2 stemriM SLES MADIARO ae BAS CLEBES ( ME RRC RR MSCS Emees IAhBTO IIE (RR < PAE EER ICMHRA I ENS )
Slide 26: 4. Pipeline
A, BARD LUIIS1 VOB
Slide 27: Pipeline overview
HAFE/ NT D541 UO © Bl (] Ni WRB MEA hist RR SERRA & aie RBI BA RAKE & HMGB1O si L9eaFk BRaneReer | STARS (TRIM2) — BHEBEYEE X12 @ ADFE KURA Hint OE cd PACER RE e TAS Sausy = #t TRIM3 git EBT) afte; 25850 = Ett TRIM4 BATFE GFE) | aust) arhik 5 PBATFE BHRARR FO-/ aLMAS MBAS GEAR) | gait. 4 Sita fad Bt
Slide 28: Redasemtide Phase 2 timeline and results schedule
HFN II1 VICKS 1 FHO EAR & seeHER ($%)202510A318ir (202610 B38) (WREMRO REIL SHR) i6MPhase2RRGERAF 36MPhase2eieP FO-Iv JO—/VbPhase2baReRAF JO—I\)bPhase2bieF “RIND) =x @ Bx EBEBPhase2 ier EBFEBPhase2 HER SE NUE Bx GFEBPhase2sT ei=BPhase2seT ie BAF EMEBPhase2xT EGPEBPhase2xT = Ett GERI) (@LFe) FFE FFE
Slide 29: Redasemtide: Phase 2 in Japan
LICAFE : RBS PRR KE eMPhase2 16M1Phase2ARART ORI *CNETOABODEDH Sets J BAI PLFEO: OE 20174128 BA WALERME TT SAMRAT! HICHTSLICLFROAME ea meee BRT TD BBY, SHAH JERR JER AES Cha BSR EGR LICLFE(1.0mg/kg) FF: 3HILLE Phase2EBESIAR FET 1A 13 OS RIARAHSS. 1011/4588 20205 3A ees xs BSA 51:4 52~ 48:2 (3~4 B11]
Slide 30: Redasemtide Phase 2 trial overview
LICLFE RES DR RK ALE) EMP hase 2K AF ESSMAB | HatHARO RAR | BRERA EME C4 ORBEA SS 3 fl REPRE IC Reto Agile | 22tt- Batt RATER OPS Sie - . LICLFFOMESREE LOMAS 5S $2 MAB Sem Nd”, BERAAHAHR KIRN
Slide 31: Redasemtide for stroke
LI CAFE Atta ER OGBEE EHR . RAID ADE 117 AES RE BFE TERRES SHEESH PS Ss PARAL 7 REDBR REO TBR (EA) #918.75A Circ J 2017; 81: 1636-16465) BARRE MM ROE Be HEE TERRE (EMEA BEHE) RAED ME <M ORE BAMA ORBRF AM ¥ RCD ICE SERB AOMAME [ a MSR eee os T 4.58508) REDSO pansn FRE~4, SRF SABRE (t- PARSER) : IME A
Slide 32: Redasemtide Phase 2b
LIRAFE BHM s FO—/\VbPhase2b Bey SEMA RABR BS ICHT SLICLFLOAME BAER BAO MH WR | 1SARDLE CHEN'S 2 5BSLLAICIRS AIRE, A—251YONIHSSAIP*AOLLL2Z2E Po a SBA RAL, SOCK, aR TiR—hA MUSSER ASEH LI CLFK(1.5mg/kg SH / TS EmH RSE kB mi SeRRROR Seite LI CLFK(1.5mg/kg #5 / TSMR AHt6796i RSA HM | 1A BIOOS PARAIRS. SA
Slide 33: Redasemtide Global Phase 2b
LIVLFKE (BtexAiMeZ) Global Phase2b RRBRAF EBSMAB | RSHRIORROMRS FILMRBINTS Stat FWA Be SL MBAR RERCA ASHE h—b F2FMAR RE | BRED ITIL BIT O BIAS 24H C ERIC, LI RLF FE CmRSOCBAA RRB D7 L— SRT Clk, FEROSES Mal SSH C MRSOcKes AIA] = | RB -BAtE ASPROAMA (Set CHEE MIRE FOMBSL/ RUYSBAE
Slide 34: Redasemtide for heart disease
LAI RLFK EmMtt b RAE RAHM ORAEAIMEEC CSIR VRRICN SS SRERS BER saint Ose Ba HIME OBEBEICNT SLY CLF FORMERVRAEOMG BRT TID SHB, MFA, FILTH, —BSR WR SOI V1 NAFAT? (CABG) ERTL EMME EBS ESERIES ——__—_—- — HES5Et EGR LICLFE BR: TSMR: 1481 RSA MAR | BARA. OAR AMEFMAR 8 RS52HRODLII-SCCLSRMORRA #25305 BM SRE
Slide 35: Redasemtide: epidemiology and rationale
LIVAFE : SAGER RAB TE PEN ARCEIC ES OU AALBERS EH (HAD) MHCAMAREOH LICLFRRSICEY MPRA 1 AEBS Re MAC LURAMBE(V CHLER<RECNEBD) THRU (EIA) BRIEKEAS SBaR-W8008A EBA R: 2,5005A International Journal of Epidemiology 2010;39:988-995 TERRE v ROR ARRORE ADH ATMA GERD “PEE CSSA (AIR: AR) PRRBMAAOEPILOLRER OAS
Slide 36: Redasemtide Phase 2 results
LICLFE : RARE EES Phase2harsee Bey ZFALRA MENS SAME. ROR WR BUA AY i ROR FY 1 IOISIF Ve RHLEZ FALERAREB SE (2 OME 7 OmAREOBX) BBTTTD | HER AFA, Pot, SR . : : oyna: et SRE EON ie mg/kg) 8:10 PSte7Ket:1061 A#t20 oe 7 ZHALEIDE ORAL RIO —D CHS RB OUST CUTMREBREITOECCAS, 2S PILS 2 ROAR AAU IA ERMA AHRROA
Slide 37: Redasemtide: liver data
LICAFE Sti RCA REIC ESHER S ARR SER *SttHTERS BRAG Sei 4 arte ECS gall HED —_ | d > 2 ASSO ERA SMEESEERSER OBE tS FAREVIZEF WIC TLILAFRICK SULA PATTER (AST, ALT), BFGEIEAR (ALB, T-Bil) Doxa HEE2 800 3. 0.2 =*p<0.01 700 7 $001 og 600 500 i 400 300 . 200 100 0) AST (IU/L) ALT (IU/L) ALB (9/dL) T-Bil (
Slide 38: Redasemtide Phase 2 liver cirrhosis
LICALFE NBER bE Phase 2karRateR Bey WHTRBBAINT SAME RAO RT , oe ‘ Zp ACA ali Se 261 CHAPIRE OBRBURM ESTE CS A SER (SEM, FEM) DTIRL steno | MIA 2 ree Kren EOE EAN YS EME CIAL. 1 AN BN CAF ARIE HBS OHM) DSIRL StF 1.5ma/ko. 90S MEGANE Tens, SUBS <EHEL, ARE OBRBUKISA IE. SKE + Da RACS BH): Aime [1 /5x 4
Slide 39: TRIM5: mechanism and data
TRIMS : aPrie 5 TRA DFR USAC EAMES LOND F RAE RSE . BBA SS TUBEMIAO MPRSIC EY, MHEL< PUBABUMNAS ES or FFRDSBL TSA LAM RH MS SES oe = BERL © REMI AS RA, MICH IN © RUBS SUS, SDF1-antik ° BARSEL<ISBMCERICLY, FAA TERS HAE AAS tt SSDF1-ank HOVE RA, RL < RRR OA RAE EK < HP RBIC AS BLINTUS HIERARCHY Ot =PI
Slide 40: SR-GT1: gene therapy
SR-GT1 :SPiiiaie oF ake IDA FARIC £2 CREAR ORAS BES BARMEOIVE TE KAR RO SCHR AEH MIAe SC fel Mia (BF-MSCs) ICIEMSVIIBIS—F UBB FEBAL, BHOKABAIHRS TSO SAUER BEE DR OK aie (RDEB) OEx vivosia FRETS {BARRE Bf-MSCs RDEBRAKEADS ~ uy oe "texeamean o>» apart » 4 & iF (LV YFIAWAKRIZ—) CORRES (HERD DRMEO EMRE
Slide 41: SR-GT1 vs competing RDEB therapies
SR-GT1 : SFAMaia oF ae fH RLU ECAR THEBES D HMDS ORDEBIM FARE BOE RR wala RB ARABI SHA | am | S2stemnim wr ERE ems | Krystal Biotech in vivox2 - math pots Ti) Abeona ee RCA RERUNS Pic) a Beate Therapeutics (BREBY) Castle Creek exvivo ——_BRARIRAESEF PSI ne * pay {6 Amryt Pharma in vivo - WPRERS Batt
Slide 42: RDEB preclinical results
RDEBET VIZ AWER REO ARI CST cH ORR = ARAICKYRDEBET IV IAICHUISRERBOVIBIAS—TFUIVNIA(CT) AERIS KAPUR SRORDEBET IYI 2 BEE Bev BrMSCS vn RERLIZ BMLOR RDEBEF ILIA EARS kf BAAR CHS KBARSISBF-MSCSOBWERRETS — wy ~ — RSRGIOBT-MSC FRROHB TKGARS SDA Be ® q Bt Mscs . 4 ae TKAURS 7 vmos—s Z 0 RAS * BR 10 ARURORA
Slide 43: SR-GT1 summary
SR-GT1 : iin Fike RDEBRBET IVINS SARUR © SAR R Mas AL ERDEBRIMET IV ETERKL, RSGAICKY AL BVICAKBENRI SCE C, ARKO R SAREE VIIDS—F iE F He, ABF-MSCs WEF BABE-MSCs + RDEB RAED IL RDEBRBET IL
Slide 44: 5. Growth strategy
5. FROME
Slide 45: Growth strategy
FROME BEATER OVE MERALOLO ORR O1 crime SILYAP Ib LILLFEO 02 EAD CHAFEE HERETAR(SR- 03 One MESA FITVO 04 ait TRIM3, TRIM4, TRIM5Id, ARRAS CORMARPIREAIV—LU ICE RENERENOBE RIE RC Fo TRIM3-TRIM4 ISS FRREREER CA SHES ERAT. SRIS AH CHRP EMOTER, WRERADITLUAP The BiaLET. TRIMS CARIC, @ IMBRERICSTLUAPIREHBL
Slide 46: Next-generation TRIM3, TRIM4
3932" TRIM3, TRIM4 (AREA ORS AS Mae AIC BRL. ICRA CANES RES SINSFRESRAE. EOPD SHIRA STS 2NTFFEREKOBER SER RT RIM3, TRIMSEL, SHAE RA. BERwER" TRIM3 RBET IMT —IORRE I »p»D» ye! ra \ SRC >) exbIc L FSCET. — SUABAOIER COBH BEBWER SERA. TRIM4 RRET ANT — TORRE *TRIM; Tissue Regeneration-Inducing Medicine
Slide 47: Partnering activities and conferences
PEFICS| Sie AAO RRO CMe SHE J < ¥ BioJ 2025.10.8~10 @biR J.P.Morgan Healthcare Conference 2026.1.12~15 @San Francisco § International 2{{e’ Convention 2026.6.22~25 @Boston 20266A Bio International ConventionkY
Slide 48: Collaboration and partners
FORA BEER HHSBICS CEERMER [BLES SNELL. ARR ORIEL BIC HEEL, 7O—/ ULB ( secavssammen_) wen 1216 one Te ne ERR FF ZOPUP 17H (2026 7A AIRE) FRI 16fF A-AbSUP TH PREAH StF Ss Oe Bes See Bae "= SS *B Rty qtVE ANY K-SYE A2vI-FyY OVP RIVE AUERUP DSU XFL MPIUA SB SUaMUN Sos +o 2 ASD 4¥UR DBVR A-APSUP ATT AIP
Slide 49: Milestones through July 2026
20264 7AMICDUTE SEIS THEBHER [CBS S RETA IZ. FRACRARO ALARA BEE SIC HEE. (2O258A ~2026F7AF COMMMTN—A Cam) Basan i HSH MILLE thle (SHG) LIRLFE KER Ate. }| ASAbSUP { x#93 J LICLFEE GE “IEDR Leenee ——‘ABRBIF-NASH eee || oe LIthFE ee markt (EB) + WetimesBhT (202548 A ~20267A)Icm oo M od right© StemRIM I
Slide 50: Alliance and financing approach
BERS ES MOMs BH My ee eae a 20206, ARAFRMEPUNAZADTI/SP S17 YAABERG - ThAIC, HH, 5 40MM (RE RSES BOM AMIORILE NEL. HAMM RIC, AF REF RAR REFS +PaRaGNSME StS ORR CARO RIEL, XUN AS SAAD BOF RAAF ME OISAREOR Leb RHEBGR ASE ae PRREDT ICE (ARES S EE RAMILDFOGH BBR AFKEFRHAAM ARREST ME RNS ORASHIR KFREFKRAR
Slide 51: Pipeline development plan
NA FS AF ERAOMAMMISEMICLSO CMS RMAC IS MIS ERE IENNPh. 2a AS RRS 384Phase2 BF RAUB Pc: Cd ° HaeTAm RABVKME ! atena FOI JO-IILPh. bb BIRIER AF T *% Phase2b ' _—}$ i — EE BRGRAE some neo ett «= ESREMPhaS2 el “ESHA BLE Seip ; Phazer | BAL EeH=EBPhase2 57 1 au BROAD RT _ ' PhIeT 1 TBD {Ste EGHEMPhase2 T
Slide 52: Outlook for fiscal year ending July 2027
2027 7AHA sBHHRIR AIC OUT REIRTAA(202510A31B) 202647 LICLFRICOWT, BARR ROA ICT CAFE'S | SSE LI CLF EIG<BERSER BRA BIC OUT, KARE RU DILUAPINCGIFE HDS SRS ES 2026 7AiA Fissit BIA TARGA ies th ALAC AORERH 1,30084AN~1,7008A 2308AN~3108AF 202777 AA FARE (RIA) Ri 2026 7AHA PSM LIVCLF ICSI SRRMEL RE KGEMPh
Slide 53: Medium-term financial plan
AA OPA PRLS AF (20198A) BRADREABE BASSES RAMRO HMEBRRORUAEROGAR PERLE (BHA) 3,050 LORE (858A) 2,350 fal S40} #8528 1,410 (98: BAR) AMIDSABA (BRA) (2020.7#4~ 2030.78) (2020.7#4~ 2026.738) (2027. 7#8~ 2030.7#8) PUK CHET BI F514 IRS FRMREES SBA RU MIRA IS 1 DORR ROR 4,135 PSER( PLERR 724 BFA 1,296 FUER
Slide 54: 6. Risks
6. UATE
Slide 55: Business risks
BROUAZD btm) Y2I Biases WSR Asi) AERATION 9 -BARMRCHACMRERR CS SUCESICLS, MEOUERPRIEDUAD H/REBS = BERD FEERBEO/\1 TST VOMMRAS OA FHROCNICHS Me = WAAR EET ORE RRO tet ICS 1 PU AP IFLR HCHVET. RB OAPERNE FAB RO RO LAREN ISUEC NIRA, SHOR O BOR AIC FERRERO NA SS 1 UICHITS, DRO BKGUBERIETIAD FAFERIEA Os
Slide 56: Appendix
Appendix
Slide 57: Management profiles
aed SF FR RURHRERCSO EH A 199ORBAMAFAFRES AEST ARE T FLAS ESR PRAM DF. SRR PRA RM, ANAL ESR MS FACS BC. 1991 FKEIIIP—VU ERAS RMA ES. 1996 FLAS ES BAS RAS c MA EMER. 2003 XIRALALRES AAA EF ORE BHBGR, 2006 HAIL. 201 OF ARALAS Bele FATT FS EBGR. 202 255 4 Ft HHHXCSO (HUE). ZO23EAMRALASE EPRICE (UE), 20
Slide 58: Company information and shareholders
mB He PASHATLUL B PRA CStetn INTs) a Se KIRA RASS ST AT-15 m RS Edt RA ((HRAMHLARCSO) RAS ae RSS EHS (ARAMA ECEO) 2006108308 B Bisse SAA ARRAPORER THLE 2-8 KBKET ISP SAP DARE - TE B BRAS BERBER OMRMABS 4,161845A 70.3% 704 (Etta So) AORATORER THLE EE 2-2 AGAZEL HARA BER /N—Dayegs— (20264 7A ARE)
Slide 59: Disclaimer and notes on forward-looking statements
ABS. ABAODLMAREICHW CHWGHEA, Ril, TAROT OMORAICEOW THY, SH RISSHORRAOWSTNE, AB FOB SE CHBLCERET SEO CLHVECA. AAMC SENSIS, BAM GHMFT SCER<RECNSCEMH '), SMGROREMBACEDESS AEE BVET. KE. AAACEMINTWSTPRPAICES Secs, SHARAF ARE SRE MRLEL CO, SHOR RICHIFSIRERO FH WIICED< tO CHY, BARUARHOUAI, MERE OHOBRRE BA